The OMER chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OMER chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The OMER stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View OMER Detailed Price Forecast - CNN Money||View OMER Detailed Summary - Google Finance|
|View OMER Detailed Summary - Yahoo! Finance||View OMER Stock Research & Analysis - Zacks.com|
|View OMER Trends & Analysis - Trade-Ideas||View OMER Major Holders - Barrons|
|View OMER Call Transcripts - NASDAQ||View OMER Breaking News & Analysis - Seeking Alpha|
|View OMER Annual Report - CompanySpotlight.com||View OMER OTC Short Report - OTCShortReport.com|
|View OMER Fundamentals - TradeKing||View OMER SEC Filings - Bar Chart|
|View Historical Prices for OMER - The WSJ||View Performance/Total Return for OMER - Morningstar|
|View the Analyst Estimates for OMER - MarketWatch||View the Earnings History for OMER - CNBC|
|View the OMER Earnings - StockMarketWatch||View OMER Buy or Sell Recommendations - MacroAxis|
|View the OMER Bullish Patterns - American Bulls||View OMER Short Pain Metrics - ShortPainBot.com|
|View OMER Stock Mentions - StockTwits||View OMER Stock Mentions - PennyStockTweets|
|View OMER Stock Mentions - Twitter||View OMER Investment Forum News - Investor Hub|
|View OMER Stock Mentions - Yahoo! Message Board||View OMER Stock Mentions - Seeking Alpha|
|View Insider Transactions for OMER - SECform4.com||View Insider Transactions for OMER - Insider Cow|
|View OMER Major Holdings Summary - CNBC||View Insider Disclosure for OMER - OTC Markets|
|View Insider Transactions for OMER - Yahoo! Finance||View Institutional Holdings for OMER - NASDAQ|
|View OMER Stock Insight & Charts - FinViz.com||View OMER Investment Charts - StockCharts.com|
|View OMER Stock Overview & Charts - BarChart||View OMER User Generated Charts - Trading View|
Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
Posted on Tuesday July 17, 2018
Omeros Corporation (OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s dopamine levels, widely recognized as central to both addictive and compulsive disorders. With preclinical data showing efficacy in multiple types of addiction and compulsive disorders, the initial target planned for OMS527 is nicotine addiction.
Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks
Posted on Friday July 13, 2018
LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
Posted on Wednesday June 27, 2018
Omeros Corporation (OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents internationally directed to PDE7 inhibitors for the treatment of all addictions and compulsive disorders.
Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Tuesday June 26, 2018
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...